Genome-wide mRNA expression profiling in vastus lateralis of COPD patients with low and normal fat free mass index and healthy controls

Abstract

BackgroundChronic Obstructive Pulmonary Disease (COPD) has significant systemic effects beyond the lungs amongst which muscle wasting is a prominent contributor to exercise limitation and an independent predictor of morbidity and mortality. The molecular mechanisms leading to skeletal muscle dysfunction/wasting are not fully understood and are likely to be multi-factorial. The need to develop therapeutic strategies aimed at improving skeletal muscle dysfunction/wasting requires a better understanding of the molecular mechanisms responsible for these abnormalities. Microarrays are powerful tools that allow the investigation of the expression of thousands of genes, virtually the whole genome, simultaneously. We aim at identifying genes and molecular pathways involved in skeletal muscle wasting in COPD.MethodsWe assessed and compared the vastus lateralis transcriptome of COPD patients with low fat free mass index (FFMI) as a surrogate of muscle mass (COPDL) (FEV1 30 ± 3.6%pred, FFMI 15 ± 0.2 Kg.m−2) with patients with COPD and normal FFMI (COPDN) (FEV1 44 ± 5.8%pred, FFMI 19 ± 0.5 Kg.m−2) and a group of age and sex matched healthy controls (C) (FEV1 95 ± 3.9%pred, FFMI 20 ± 0.8 Kg.m−2) using Agilent Human Whole Genome 4x44K microarrays. The altered expression of several of these genes was confirmed by real time TaqMan PCR. Protein levels of P21 were assessed by immunoblotting.ResultsA subset of 42 genes was differentially expressed in COPDL in comparison to both COPDN and C (PFP < 0.05; −1.5 ≥ FC ≥ 1.5). The altered expression of several of these genes was confirmed by real time TaqMan PCR and correlated with different functional and structural muscle parameters. Five of these genes (CDKN1A, GADD45A, PMP22, BEX2, CGREF1, CYR61), were associated with cell cycle arrest and growth regulation and had been previously identified in studies relating muscle wasting and ageing. Protein levels of CDKN1A, a recognized marker of premature ageing/cell cycle arrest, were also found to be increased in COPDL.ConclusionsThis study provides evidence of differentially expressed genes in peripheral muscle in COPD patients corresponding to relevant biological processes associated with skeletal muscle wasting and provides potential targets for future therapeutic interventions to prevent loss of muscle function and mass in COPD.Electronic supplementary materialThe online version of this article (doi:10.1186/s12931-014-0139-5) contains supplementary material, which is available to authorized users.

Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial

“…Using 30mg pioglitazone for 2 weeks increased to 45mg for 10 weeks there were no significant differences in the airway hyper-responsiveness to methacholine, FeNO or lung function between treatment and placebo. Recruitment was halted early (as in our study) due to the impact of emerging safety concerns surrounding the potential risk of bladder cancer affecting recruitment, lack of efficacy signal and significant weight gain in pioglitazone treated patients [19]. The thiazolidinediones are associated with significant adverse effects when administered systemically and these studies support our conclusion that systemic treatment with pioglitazone is not associated with beneficial effects on asthma control.…”

The association between environmental tobacco smoke exposure and childhood respiratory disease: a review

“…A systematic review found that postnatal maternal smoking was strongly associated with bronchiolitis (OR 2.51, 95% CI 1.58–3.97) [36]. More recently, prenatal ETS exposure and heavy postnatal maternal smoking were both associated with an increased risk of hospitalization for bronchiolitis in the first year of life; however, postnatal exposure increased the risk by twofold compared to prenatal ETS exposure [44]. Further, both prenatal and postnatal maternal smoking were associated with an increased risk for admission to ICU: OR = 1.51 (95% CI 1.14–2.00) for prenatal and OR = 1.95 (95% CI 1.13–3.37) for postnatal exposure [45].…”

The rat model of COPD skeletal muscle dysfunction induced by progressive cigarette smoke exposure: a pilot study

“…Moreover, NAGS showed no significant difference between the two groups, indicating that body weight was an essential factor affecting muscle function [34]. Muscle mass may play a key role: the studies [35][36][37] available in the literature prove that protein synthesis of myocyte is weakened and the muscle growth is inhibited in COPD, which means that the modeling process may inhibit muscle growth and then inhibit muscle function. Although these hypotheses are not reflected in our results, it suggests that CSE may cause skeletal muscle dysfunction by inhibiting muscle growth, taking into account the importance of muscle mass in body weight.…”